June 10, 2008 – LifeScan, Inc., maker of the leading OneTouch® Brand of blood glucose meters for people with diabetes, and ResMed, Inc. (NYSE: RMD), a leading manufacturer of medical devices for the diagnosis and treatment of sleep apnea, today announced an exclusive co-marketing agreement designed to improve the lives of people with type 2 diabetes and sleep-disordered breathing (SDB). The joint work of the two companies will focus on educational and cross-promotional efforts intended to benefit the patients and healthcare professionals served by both companies.
The goal is to build awareness among healthcare professionals of the overlap of these two conditions, trigger new approaches to patient care, and ultimately improve the rate of treating patients suffering from both SDB and diabetes... LifeScan's Press Release -
Blog Archive
-
▼
2008
(56)
-
▼
June
(6)
- Lilly : FDA Approves Cymbalta for the Management o...
- Transcept Pharmaceuticals : Intent to Submit New D...
- Sanofi-aventis : Ambien CR Improved Insomnia and D...
- ResMed and LifeScan : Co-Marketing Agreement Focu...
- Pipex Pharmaceuticals : Oral Flupirtine Receives I...
- UCB : Neupro recommended for approval in Europe fo...
-
▼
June
(6)